Document is current
Any future updates will be listed below
-
Authors
Bloos, Frank https://orcid.org/0000-0002-0767-7941
Held, Jürgen https://orcid.org/0000-0003-1130-9727
Kluge, Stefan https://orcid.org/0000-0001-8391-3988
Simon, Philipp https://orcid.org/0000-0003-2696-3254
Kogelmann, Klaus https://orcid.org/0000-0003-4308-9319
de Heer, Geraldine https://orcid.org/0000-0003-1950-8683
Kuhn, Sven-Olaf https://orcid.org/0000-0003-2961-4578
Jarczak, Dominik https://orcid.org/0000-0003-0480-2089
Motsch, Johann
Hempel, Gunther https://orcid.org/0000-0002-9705-5184
Weiler, Norbert
Weyland, Andreas https://orcid.org/0000-0002-3468-6915
Drüner, Matthias https://orcid.org/0000-0001-9979-5904
Gründling, Matthias https://orcid.org/0000-0002-2498-1953
Meybohm, Patrick https://orcid.org/0000-0002-2666-8696
Richter, Daniel https://orcid.org/0000-0003-1786-5919
Jaschinski, Ulrich https://orcid.org/0000-0002-3318-0234
Moerer, Onnen https://orcid.org/0000-0002-4210-388X
Günther, Ulf
Schädler, Dirk https://orcid.org/0000-0002-5745-4797
Weiss, Raphael
Putensen, Christian
Castellanos, Ixchel https://orcid.org/0000-0001-7091-5423
Kurzai, Oliver https://orcid.org/0000-0002-7277-2646
Schlattmann, Peter https://orcid.org/0000-0001-7420-7707
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
Bauer, Michael https://orcid.org/0000-0002-1521-3514
Thomas-Rüddel, Daniel https://orcid.org/0000-0001-9143-8566
,
Jaschinski, Ulrich
Putensen, Christian
Drüner, Matthias https://orcid.org/0000-0001-9979-5904
Castellanos, Ixchel https://orcid.org/0000-0001-7091-5423
Schmidt, Stefanie
Wehrfritz, Andreas
Kränzlein, Diana
Held, Jürgen https://orcid.org/0000-0003-1130-9727
Zacharowski, Kai
Mutlak, Haitham
Lindau, Simone
Wiedenbeck, Carolin
Mörer, Onnen
Kuhn, Sven-Olaf https://orcid.org/0000-0003-2961-4578
Gründling, Matthias https://orcid.org/0000-0002-2498-1953
Kluge, Stephan
de Heer, Geraldine
Jarczak, Dominik https://orcid.org/0000-0003-0480-2089
Motsch, Johann
Richter, Daniel https://orcid.org/0000-0003-1786-5919
Weigand, Markus A.
Bloos, Frank https://orcid.org/0000-0002-0767-7941
Bauer, Michael https://orcid.org/0000-0002-1521-3514
Thomas-Rüddel, Daniel https://orcid.org/0000-0001-9143-8566
Schlattmann, Peter https://orcid.org/0000-0001-7420-7707
Lehmann, Thomas
Weiler, Norbert
Schädler, Dirk https://orcid.org/0000-0002-5745-4797
Cornely, Oliver A. https://orcid.org/0000-0001-9599-3137
Simon, Philipp https://orcid.org/0000-0003-2696-3254
Hempel, Gunther https://orcid.org/0000-0002-9705-5184
Weiss, Raphael
Zarbock, Alexander
Günther, Ulf
Rohe, Georg
Weyland, Andreas https://orcid.org/0000-0002-3468-6915
Kurzai, Oliver https://orcid.org/0000-0002-7277-2646
Walter, Grit
Meybohm, Patrick https://orcid.org/0000-0002-2666-8696
Helmer, Philipp
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02734550 at ClinicalTrials.govDocuments that mention this clinical trial
(1 → 3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial
https://doi.org/10.1007/s00134-022-06733-x
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01EO1502)
Deutsche Forschungsgemeinschaft (390713860, PU219/2-3)
Universitätsklinikum Jena
- License Information
-
More Information
Article History
Received: 20 February 2022
Accepted: 7 May 2022
First Online: 16 June 2022
Declarations
:
: FB received honoraria for an expert board meeting by Baxter. Prof. Cornely reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. JH received grants and speaker honoraria from Pfizer, speaker honoraria from Gilead and consumables/test kits from Associates of Cape Cod. SK received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from Astra, Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. KK received honoraria for lecturing from Cytosorbents, Fresenius and Sedana. CP received lecture fees from Astra, C.R.Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. He received consultant fees from Bayer, Fresenius, Gilead, MSD and Pfizer. He also received consultant fees from Messer, Pluristem, and Sedana and received lecture fees from Dräger Med. Inc. and Medronic. OM received honoraria for lectures during workshops on hemodynamic monitoring, supported by Pulsion (Maquet Critical Care) and for two lectures during industrial sessions at national congresses (HillRom, HepaWash); Unrestricted Research Grant from CSL Behring. DR has received support for attending meetings and/or travels from Gilead Sciences Inc., MSD, Pfizer. AW reported receiving honoraria for lecturing from Getinge and receiving personal fees from TEVA for consulting. No other disclosures were reported.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Jena University Hospital and by the responsible Ethics Committees of the participating study centers.
: Written informed consent was obtained from all patients or their legal representatives, if available. In cases where consent could neither be obtained from the patient nor a legal representative in time before enrollment, the local ethics committee approved a delayed consent process. During this process the patient’s inability to provide consent was confirmed by an independent physician. As soon as the legal representative of the patient was available, written informed consent was immediately obtained, otherwise the patient was withdrawn from the study and all study procedures were ended.
: Not applicable.
